COST-EFFECTIVENESS ANALYSIS OF LURASIDONE AND OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA

被引：0
|
作者：
Priyadarshini, M. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1380
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH40
引用
收藏
页码：A188 / A189
页数：2
相关论文
共 50 条
  • [1] VALIDATING A COST-EFFECTIVENESS ANALYSIS COMPARING OLANZAPINE WITH ZIPRASIDONE IN THE TREATMENT OF SCHIZOPHRENIA
    Graham, C.
    Mauskopf, J.
    Lawson, A. H.
    Ascher-Svanum, H.
    Bruhn, D.
    Watson, P. R.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A113 - A113
  • [2] Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia
    Ascher-Svanum, Haya
    Stensland, Michael D.
    Peng, Xiaomei
    Faries, Douglas E.
    Stauffer, Virginia L.
    Osuntokun, Olawale O.
    Kane, John M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (01) : 115 - 122
  • [3] A cost-effectiveness comparison of olanzapine and risperidone in the treatment of schizophrenia in Italy
    Beard, S
    Lothgren, M
    Giudi, L
    Ramacciotti, F
    Nardini, M
    Berardi, D
    [J]. VALUE IN HEALTH, 2002, 5 (06) : 515 - 515
  • [4] Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China
    Yi, Zhan-Miao
    Men, Peng
    Qu, Shuli
    Li, Chaoyun
    Yu, Xin
    Zhai, Suodi
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (03) : 313 - 320
  • [5] COST-EFFECTIVENESS ANALYSIS OF AMISULPRIDE AND OLANZAPINE FOR PATIENTS WITH SCHIZOPHRENIA IN CHINA
    Men, P.
    Yi, Z.
    Li, C.
    Qu, S.
    Xiong, T.
    Yu, X.
    Zhai, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S185 - S185
  • [6] Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia
    Bounthavong, Mark
    Okamoto, Mark P.
    [J]. JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2007, 13 (03) : 453 - 460
  • [7] A COST-EFFECTIVENESS ANALYSIS OF PALIPERIDONE PALMITATE VERSUS OLANZAPINE PAMOATE IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY
    Einarson, T. R.
    Vicente, C.
    Zilbershtein, R.
    Piwko, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A292 - A293
  • [8] Cost-effectiveness of amisulprid compared to risperidone and olanzapine in the treatment of schizophrenia in Poland
    Kowalik, E.
    Jakubczyk, M.
    Lis, J.
    Niewada, M.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A314 - A314
  • [9] Cost-effectiveness of orally dissolving olanzapine tablets in the treatment of schizophrenia in the USA
    Ascher-Svanum, H.
    Furiak, N. M.
    Klein, R. W.
    Smolen, L. J.
    Watson, P. R.
    Lawson, A. H.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A119 - A119
  • [10] COST-EFFECTIVENESS OF OLANZAPINE IN THE FIRST-LINE TREATMENT OF SCHIZOPHRENIA IN CHINA
    Zhao, J.
    Jiang, K.
    Li, Q.
    Zhang, Y. L.
    Cheng, Y.
    Lin, Z.
    Xuan, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S76 - S77
12345